9 completed, 6 active not recruiting, 6 recruiting, 4 terminated. 29 Phase 2, 8 Phase 1, 1 Phase 3.
Follow Vyxeos: new trials by email Literature Review of Vyxeos trials Research Report on Vyxeos
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment Cytarabine, Venetoclax, CPX-351 - Leukemia, Myeloid, Acute | Phase 2 | Not yet recruiting | Eastern Cooperative Oncology Group | 184 | 2024-10-23 | 2024-07-03 |
| Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 335 | 2024-09-25 | 2026-11-02 |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2000 | 2024-06-18 | 2026-11-02 |
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Children's Oncology Group | 2023-08-01 | 2023-09-01 | |
| Phase IB/II of CPX-351 for Relapse Prevention in AML CPX-351 - Acute Myeloid Leukemia (AML) in Remission | Phase 1 / Phase 2 | Recruiting | Georgetown University | 24 | 2023-05-22 | 2026-03-23 |
| Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 49 | 2022-08-24 | 2026-06-30 |
| Vyxeos for Induction of Low- or Intermediate-risk. Vyxeos, Mylotarg - Leukemia, Myeloid, Acute | Phase 2 | Active not recruiting | Shaare Zedek Medical Center | 20 | 2022-08-07 | 2026-10-08 |
| CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2 | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 1 | 2021-08-09 | 2024-05-23 |
| CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Phase 2 | Completed | Roswell Park Cancer Institute | 21 | 2021-07-29 | 2026-09-08 |
| Venetoclax + Azacitidine vs. Induction Chemotherapy in AML Cytarabine, Idarubicin, Daunorubicin - Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Massachusetts General Hospital | 172 | 2021-05-20 | 2026-05-12 |
| Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction Liposome-encapsulated Daunorubicin-Cytarabine - Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Persistent Disease | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 28 | 2021-01-29 | 2026-09-09 |
| CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Ivosidenib, Liposome-encapsulated Daunorubicin-Cytarabine - Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2020-12-30 | 2026-08-25 |
| Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia. Fludarabine, Vyxeos - Acute Myeloid Leukemia, Adult, AML | Phase 2 | Terminated | University of California, San Diego | 2 | 2020-08-05 | 2022-09-22 |
| A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia CPX-351, Quizartinib - Leukemia, Myeloid, Acute | Phase 2 | Terminated | SCRI Development Innovations, LLC | 1 | 2020-06-03 | 2023-12-05 |
| CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients Liposome-encapsulated Daunorubicin-Cytarabine, Cladribine, Cytarabine - Acute Myeloid Leukemia, Myeloid Neoplasm | Phase 2 | Completed | Fred Hutchinson Cancer Center | 60 | 2020-05-27 | 2026-06-29 |
| Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Liposome-encapsulated Daunorubicin-Cytarabine, Quizartinib - Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 52 | 2020-05-27 | 2026-06-02 |
| A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT Vyxeos, Fludarabine, Busulphan - Acute Myeloid Leukaemia, High-risk Myelodysplastic Syndrome | Phase 2 / Phase 3 | Active not recruiting | University of Birmingham | 333 | 2020-01-27 | 2026-05-05 |
| HDM201 Added to CT in R/R or Newly Diagnosed AML HDM201, cytarabine, anthracycline - Leukemia, Myeloid, Acute | Phase 1 / Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2019-11-15 | 2020-01-09 | |
| Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML CPX-351, Daunorubicin, Cytarabine - MDS, AML | Phase 2 | Completed | GWT-TUD GmbH | 150 | 2019-08-19 | 2026-09-10 |
Showing 20 of 29. Sign in to see all of them.
Leukemia, Myeloid, Acute (24) · Myelodysplastic Syndromes (5) · Myeloproliferative Disorders (5) · Burkitt Lymphoma (2) · Leukemia, Monocytic, Acute (2) · Leukemia, Myelomonocytic, Chronic (2) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphoid (1) · Neoplasm, Residual (1) · Polycythemia Vera (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Myelofibrosis (1) · Thrombocythemia, Essential (1)
M.D. Anderson Cancer Center (5) · National Cancer Institute (NCI) (4) · Children's Oncology Group (2) · Fred Hutchinson Cancer Center (2) · Ohio State University Comprehensive Cancer Center (2) · Eastern Cooperative Oncology Group (1) · GWT-TUD GmbH (1) · Georgetown University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jonsson Comprehensive Cancer Center (1) · Massachusetts General Hospital (1) · Novartis Pharmaceuticals (1) · Roswell Park Cancer Institute (1) · SCRI Development Innovations, LLC (1) · Shaare Zedek Medical Center (1)
United States (22) · Canada (3) · Puerto Rico (2) · Austria (1) · Germany (1) · Israel (1) · United Kingdom (1)
Amir T Fathi, MD (1) · Bijal Shah, M.D. (1) · Caspian Oliai, MD (1) · Charles Craddock, Professor (1) · Chezi Ganzel, DR (1) · Courtney DiNardo, MD (1) · Ehab Atallah, MD (1) · Ehab L Atallah (1) · Eunice Wang, MD (1) · Filippo Milano (1) · Ghayas Issa (1) · Gregory K Behbehani, MD, PhD (1) · Jerald P Radich (1) · Joshua F Zeidner (1) · Kimberley Doucette, MD (1)
PMID 32401633, PMID 33208914, PMID 35450817, PMID 36892565, PMID 36902217, PMID 38000343, PMID 40298352, PMID 40401707, PMID 42559085, PMID 42685316, PMID 42835577
U10CA180886 (2), U10CA180888 (2), 2018 (1), P30CA036727 (1), U10CA180820 (1), UM1CA186712 (1)